Overview

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.
Phase:
Phase 2
Details
Lead Sponsor:
AIM ImmunoTech Inc.
Collaborator:
Amarex Clinical Research
Treatments:
Poly I-C
poly(I).poly(c12,U)